Oppenheimer Upgrades Teva Pharmaceutical Industries Ltd (ADR) to Outperform

Brokerage firm Oppenheimer Upgrades its rating on Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA). The shares have been rated Outperform. Previously, the analysts had a Perform rating on the shares. The rating by Oppenheimer was issued on Sep 2, 2016.

In a different note, On Aug 24, 2016, BTIG Research said it Maintains its rating on Teva Pharmaceutical Industries Ltd (ADR). The shares have been rated ‘Buy’ by the firm. On Jul 18, 2016, HSBC said it Upgrades its rating on Teva Pharmaceutical Industries Ltd (ADR). The shares have been rated ‘Buy’ by the firm. On Jul 14, 2016, Oppenheimer said it Maintains its rating on Teva Pharmaceutical Industries Ltd (ADR). In the research note, the firm Lowers the price-target to $77.00 per share. The shares have been rated ‘Outperform’ by the firm. On Jul 14, 2016, Jefferies said it Maintains its rating on Teva Pharmaceutical Industries Ltd (ADR). In the research note, the firm Lowers the price-target to $72.00 per share. The shares have been rated ‘Buy’ by the firm.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) made into the market gainers list on Thursdays trading session with the shares advancing 1.01% or 0.51 points. Due to strong positive momentum, the stock ended at $50.9, which is also near the day’s high of $51.21. The stock began the session at $50.18 and the volume stood at 72,72,777 shares. The 52-week high of the shares is $66.55 and the 52 week low is $48.01. The company has a current market capitalization of $46,523 M and it has 91,40,00,000 shares in outstanding.

Teva Pharmaceutical Industries Ltd (ADR)(TEVA) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $5.04B. Analysts had an estimated revenue of $4.85B. Earnings per share were $1.25. Analysts had estimated an EPS of $1.20.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company’s generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines which manufactures and sells generic pharmaceutical products in several dosage forms including tablets capsules injectables inhalants liquids ointments and creams and Specialty medicines which delivers solutions to patients and providers via medicines devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda Trisenox Granix Synribo Lonquex Tevagrastim/Ratiograstim Myocet Trisenox and Eporatio. Its women’s health portfolio includes ParaGard Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *